

# CITATION REPORT

List of articles citing

## Mechanism of action of hydroxychloroquine as an antirheumatic drug

DOI: 10.1016/s0049-0172(10)80012-5

Seminars in Arthritis and Rheumatism, 1993, 23, 82-91.

**Source:** <https://exaly.com/paper-pdf/23903130/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
344	Inhibition of human immunodeficiency virus infectivity by chloroquine. <b>1990</b> , 6, 481-9		118
343	Hydroxychloroquine and pain thresholds. <b>1995</b> , 38, 445-6		2
342	Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. <b>1995</b> , 73, 73-7		28
341	Category III Symptom-Modifying Antirheumatic Drugs. <b>1995</b> , 3, 196-217		6
340	Antimalarial Drugs. <b>1995</b> , 4, 219-234		5
339	Disease-modifying antirheumatic drugs. Potential effects in older patients. <b>1995</b> , 7, 420-37		21
338	Okadaic acid-like toxin in systemic lupus erythematosus patients: hypothesis for toxin-induced pathology, immune dysregulation, and transactivation of herpesviruses. <b>1996</b> , 47, 217-25		1
337	The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?. <b>1996</b> , 5, 6-10		47
336	The Use of Slower-Acting (Class III) Symptom-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. <b>1996</b> , 5, 309-325		
335	Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. <b>1996</b> , 5, 31-36		96
334	The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis—the French Experience. <b>1996</b> , 5, 45-49		1
333	Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. <b>1996</b> , 5, 4-10		55
332	Section Reviews: Biologicals & Immunologicals: Sjögren's syndrome: Pathogenesis and prospects for therapy. <b>1996</b> , 5, 1127-1153		
331	Undiagnosed polyarthritis with positive anti-Ro/SSA antibodies following a biliopancreatic bypass for morbid obesity. <i>Clinical Rheumatology</i> , <b>1996</b> , 15, 514-5	3.9	2
330	Respiratory function in systemic lupus erythematosus: relation with activity and severity. <b>1996</b> , 5, 38-43		90
329	Retinal toxicity in long term hydroxychloroquine treatment. <b>1996</b> , 55, 187-9		68
328	The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. <b>1997</b> , 24, 201-10		53

327	Treatment of rheumatoid arthritis. <b>1997</b> , 81, 57-84	9
326	Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction. <b>1997</b> , 227, 169-72	18
325	Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 27, 277-92	5:3 172
324	Biological agents in rheumatoid arthritis: which ones could be used in combination?. <b>1998</b> , 9, 303-24	3
323	Hydroxychloroquine: past, present, future. <b>1998</b> , 7, 65-7	30
322	Antimalarial drugs in pregnancy. <b>1998</b> , 107, 125-7	8
321	Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. <b>1999</b> , 160, 192-7	127
320	CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. <b>1999</b> , 11, 2015-24	79
319	Bacterial CpG DNA activates immune cells to signal infectious danger. <b>1999</b> , 73, 329-68	241
318	Structure-activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory CpG-oligodeoxynucleotides. <b>1999</b> , 9, 1819-24	25
317	Anti-DNA autoantibodies and systemic lupus erythematosus. <b>1999</b> , 83, 125-39	49
316	Novel therapies for inflammatory bowel disease. <b>1999</b> , 28, 323-51	26
315	Hydroxychloroquine inhibits matrix metalloprotease activity in experimental calcium pyrophosphate dihydrate (CPPD) crystal induced inflammation in the rat subcutaneous air pouch. <b>2000</b> , 8, 113-121	2
314	Functional defects of NK cells treated with chloroquine mimic the lytic defects observed in perforin-deficient mice. <b>2000</b> , 165, 5048-53	33
313	The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. <b>2000</b> , 9, 92-5	53
312	Antimalarials: unapproved uses or indications. <b>2000</b> , 18, 17-35	42
311	Antimalarials--the 'real' advance in lupus. <b>2001</b> , 10, 385-7	55
310	Novel approaches to the treatment of chronic graft-versus-host disease. <b>2001</b> , 10, 909-23	5

309	Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. <b>2002</b> , 11, 71-81	53
308	Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. <b>2002</b> , 8, 648-55	18
307	Discovery of novel targets of quinoline drugs in the human purine binding proteome. <b>2002</b> , 62, 1364-72	209
306	Quinacrine increases endothelial nitric oxide release: role of superoxide anion. <b>2002</b> , 436, 159-63	5
305	Methotrexate versus chloroquine in the treatment of rheumatoid arthritis. <b>2003</b> , 6, 26-31	1
304	Chloroquine induces activation of nuclear factor-kappaB and subsequent expression of pro-inflammatory cytokines by human astroglial cells. <b>2003</b> , 84, 1266-74	39
303	Bis-4-aminoquinolines: novel triple-helix DNA intercalators and antagonists of immunostimulatory CpG-oligodeoxynucleotides. <b>2003</b> , 11, 1079-85	22
302	Uso de los antimaláricos en dermatología. <b>2003</b> , 18, 515-518	2
301	Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. <b>2003</b> , 9, 714-21	19
300	Chronic ulcerative stomatitis: clinical, histopathologic, and immunopathologic findings. <b>2003</b> , 96, 718-26	33
299	Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. <b>2003</b> , 12, 297-301	12
298	Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , <b>2004</b> , 33, 336-51	53 94
297	Reactive oxygen species mediate chloroquine-induced expression of chemokines by human astroglial cells. <b>2004</b> , 47, 9-20	62
296	Risk factors for osteoporosis in female patients with systemic lupus erythematosus. <b>2004</b> , 13, 724-30	32
295	Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. <b>2004</b> , 4, 223-34	82
294	Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. <b>2004</b> , 44, 1034-45	5
293	New therapies for systemic lupus erythematosus. <b>2005</b> , 140, 205-12	39
292	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. <b>2005</b> , 52, 1473-80	261

291	The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2. <b>2005</b> , 25, 332-5		21
290	Rheumatoid arthritis: an overview of new and emerging therapies. <b>2005</b> , 45, 751-62		114
289	Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. <b>2005</b> , 44, 449-55		60
288	Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable?. <b>2005</b> , 64, 438-48		17
287	[Antimalarials: an update in rheumatic diseases]. <b>2006</b> , 2, 190-201		8
286	Hydroxychloroquine in the treatment of chronic erythema nodosum. <b>1995</b> , 132, 661-2		15
285	The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. <b>2006</b> , 63, 299-303		31
284	Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. <b>2006</b> , 54, 3079-86		167
283	Synthesis of 2-phenylquinolin-4-amines substituted with diverse amino and aminoalkyl groups. <i>Journal of Heterocyclic Chemistry</i> , <b>2006</b> , 43, 1613-1620	1.9	1
282	Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. <b>2006</b> , 15, 366-70		129
281	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. <b>2006</b> , 1, 225-233		5
280	SYNTHESIS OF SUBSTITUTED 1,2,3,4-TETRAHYDROBENZO [b] [1,6] NAPHTHYRIDINES. <b>2006</b> , 12,		
279	Therapy of cutaneous lupus erythematosus. <b>2006</b> , 1, 105-120		2
278	IMPROVED SYNTHESIS OF SUBSTITUTED 2-ARYL-N-[2-(DIMETHYLAMINO)ETHYL]QUINOLIN-4-AMINES AND THEIR ACTIVITY AS ANTAGONISTS OF IMMUNOSTIMULATORY CpG-OLIGODEOXYNUCLEOTIDES. <b>2007</b> , 13,		1
277	Chronic ulcerative stomatitis: diagnostic and management challenges--four new cases and review of literature. <b>2007</b> , 104, 194-203		31
276	A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. <b>2007</b> , 13, 1201-6		16
275	Chloroquine is therapeutic in murine experimental model of paracoccidioidomycosis. <b>2007</b> , 50, 133-43		9
274	Secondary myelodysplastic syndrome after hydroxychloroquine therapy. <b>2007</b> , 86, 531-4		5

273	Chronic ulcerative stomatitis. <b>2008</b> , 14, 383-9	37
272	Lyme arthritis: pathogenesis, clinical presentation, and management. <b>2008</b> , 22, 289-300, vi-vii	48
271	Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. <b>2008</b> , 100, 403-11; quiz 412-4, 468	51
270	Therapeutics and immune-mediated skin disease. <b>2008</b> , 10, 359-72	
269	Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. <b>2008</b> , 15, 1497-504	35
268	Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. <b>2008</b> , 112, 1687-95	166
267	Pharmacotherapy of systemic lupus erythematosus. <b>2009</b> , 10, 1481-94	24
266	Facile synthesis of 1,2,3,4- tetrahydrobenzo[b][1,6]naphthyridines. <b>2009</b> , 15,	1
265	Hypothetical hormonal mechanism by which potassium-rich diets benefit patients with rheumatoid arthritis. <b>2009</b> , 73, 564-8	4
264	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. <b>2009</b> , 26, 273-93	19
263	Hydroxychloroquine-induced myopathy. <b>2010</b> , 16, 28-31	26
262	Cooperative binding of a quinoline derivative to an RNA stem loop containing a dangling end. <b>2010</b> , 20, 3134-7	10
261	Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. <b>2010</b> , 54, 871-81	72
260	Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. <b>2010</b> , 26, 339-42	12
259	Rheumatoid Arthritis. <b>2010</b> , 114-141	2
258	Cryptococcal immune reconstitution syndrome during steroid withdrawal treated with hydroxychloroquine. <i>International Journal of Infectious Diseases</i> , <b>2011</b> , 15, e70-3	10.5 19
257	Unconventional treatment options in severe asthma: an overview. <b>2011</b> , 14, 387-99	7
256	Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. <b>2011</b> , 118, 3263-72	139

- 255 Atherosclerosis risk in antiphospholipid syndrome. **2011**, 6, 583-593
- 254 Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. **2011**, 205, 576.e7-14 47
- 253 Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation. **2011**, 72, 689-702 3
- 252 Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. **2011**, 129, 30-9 141
- 251 Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. **2011**, 108, 3689-94 84
- 250 Orbital sarcoidosis treated with hydroxychloroquine. **2011**, 30, 13-5 7
- 249 Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. **2012**, 18, 1543-55 39
- 248 Immunotherapies in rheumatologic disorders. **2012**, 96, 475-96, ix-x 28
- 247 [Conventional basis therapy of rheumatoid arthritis. Effects within and outside cells]. **2012**, 71, 468-72
- 246 Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. **2012**, 2, 241-5 14
- 245 Antimalarials: Reversing the autoimmune Enal-area. **2012**, 7, 97-101
- 244 Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens. **2012**, 18, 546-56 6
- 243 New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. **2012**, 8, 522-33 145
- 242 Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes. **2012**, 62, 267-74 27
- 241 Azithromycin distinctively modulates classical activation of human monocytes in vitro. **2012**, 165, 1348-60 67
- 240 Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. **2012**, 39, 531-5 19
- 239 Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. **2013**, 14, 64 20
- 238 Chloroquine: modes of action of an undervalued drug. **2013**, 153, 50-7 92

237	Antimalarial Medications. <b>2013</b> , 601-608	3
236	Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. <b>2013</b> , 31, 1717-24	23
235	Etiology and therapeutic management of erythema nodosum during pregnancy: an update. <b>2013</b> , 14, 215-22	18
234	LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases. <b>2013</b> , 37, 1014-21	18
233	Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. <b>2014</b> , 66, 1619-26	55
232	Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. <b>2014</b> , 30, 355-62	12
231	Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. <b>2014</b> , 30, 1706-15	92
230	Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection. <b>2014</b> , 58, 584-6	8
229	Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. <b>2014</b> , 7, 1033-46	51
228	Kikuchi-Fujimoto disease: retrospective study of 91 cases and review of the literature. <b>2014</b> , 93, 372-382	102
227	Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. <b>2014</b> , 20, 3159-73	101
226	Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. <b>2014</b> , 53, 2035-43	9
225	Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios. <b>2014</b> , 105, 243-252	27
224	The diagnosis and management of acute and chronic urticaria: 2014 update. <b>2014</b> , 133, 1270-7	389
223	Treatment of Autoimmune Disease: Established Therapies. <b>2014</b> , 1209-1220	
222	Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. <b>2014</b> , 92, 124-32	32
221	A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. <b>2014</b> , 5, 77-85	52
220	Antimalarials in dermatology: mechanism of action, indications, and side effects. <b>2014</b> , 105, 243-52	14



219	Integrative phenotyping framework (iPF): integrative clustering of multiple omics data identifies novel lung disease subphenotypes. <b>2015</b> , 16, 924	50
218	Systemic lupus erythematosus and the role of the GP. <b>2015</b> , 26, 31-35	
217	Molecular targets in arthritis and recent trends in nanotherapy. <b>2015</b> , 10, 5407-20	24
216	Hydroxychloroquine Retinopathy. <b>2015</b> , 22, 140	
215	Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target. <b>2015</b> , 6, 252	40
214	Killing of <i>Staphylococcus aureus</i> in murine macrophages by chloroquine used alone and in combination with ciprofloxacin or azithromycin. <b>2015</b> , 8, 29-47	23
213	Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143771	3-7 15
212	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <b>2015</b> , 14, 358-62	84
211	Cyclic nucleotide signalling in kidney fibrosis. <b>2015</b> , 16, 2320-51	34
210	Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. <b>2015</b> , 98, 479-87	43
209	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. <b>2015</b> , 23, 231-69	300
208	Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. <b>2015</b> , 243, 11-8	64
207	In silico analysis reveals the anti-malarial potential of quinolinyl chalcone derivatives. <b>2015</b> , 33, 961-77	24
206	Drugs for Parasitic Infections: Advances in the Discovery of New Antimalarials. <b>2016</b> ,	2
205	Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis. <b>2016</b> , 19, 512-20	10
204	VOLUMETRIC SINGLE-LAYER INNER RETINAL ANALYSIS IN PATIENTS WITH HYDROXYCHLOROQUINE TOXICITY. <b>2016</b> , 36, 1941-50	9
203	Discoveries of conventional synthetic disease modifying anti-rheumatic drugs: Serendipity or flawless reasoning?. <b>2016</b> , 11, 32-38	3
202	Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes. <b>2016</b> , 16, 91	3

201	Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes. <b>2016</b> , 14, 1275-82		4
200	A Systematic Study on the Synthesis of n-Butyl Substituted 8-Aminoquinolines. <i>Journal of Heterocyclic Chemistry</i> , <b>2016</b> , 53, 263-270	1.9	1
199	Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. <b>2017</b> , 79, 99-104		7
198	Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges. <b>2017</b> , 177, 56-66		74
197	Hydroxychloroquine retinopathy. <b>2017</b> , 31, 828-845		99
196	Subacute cutaneous lupus erythematosus. <b>2017</b> , 163, 149-151		1
195	The gathering storm: hydroxychloroquine retinopathy screening in the U.K. <b>2017</b> , 176, 1420-1421		4
194	Expression of Toll-Like Receptors in Peripheral Blood Mononuclear Cells of Patients with Primary Sjögren's Syndrome. <b>2017</b> , 85, 220-226		12
193	Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. <b>2018</b> , 22, 873-882		5
192	Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 689-693	3.9	5
191	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. <b>2017</b> , 617-643		0
190	Novel organometallic chloroquine derivative inhibits tumor growth. <b>2018</b> , 119, 5921-5933		12
189	Hydroxychloroquine affects bone resorption both in vitro and in vivo. <b>2018</b> , 233, 1424-1433		17
188	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <b>2018</b> , 77, 98-103		117
187	Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. <b>2018</b> , 27, 847-852		24
186	Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. <b>2018</b> , 38, 646-652		20
185	Micropapular Cutaneous Sarcoidosis Reviewed. <b>2018</b> , 234, 220-225		2
184	Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease. <b>2018</b> , 82, 158-170		15

183	Renal Manifestations of Rheumatoid Arthritis. <b>2018</b> , 44, 571-584	16
182	Spontaneous hypertrophic cardiomyopathy in a cynomolgus macaque (). <b>2018</b> , 31, 49-54	4
181	Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. <b>2018</b> , 168, 385-395	39
180	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. <b>2018</b> , 195, 1-7	38
179	Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. <b>2018</b> , 26, 1141-1149	45
178	Use of immunomodulators to treat endometriosis. <b>2019</b> , 60, 56-65	9
177	Vitamin D treatment for chronic urticaria: a case report. <b>2019</b> , 13, 193	1
176	Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems. <b>2019</b> , 9,	40
175	Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. <b>2019</b> , 112, 757-762	6
174	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <b>2019</b> , 18, 415-425	15
173	Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. <b>2019</b> , 2, 98-106	13
172	Recognition and management of systemic lupus erythematosus. <b>2019</b> , 30, 13-20	
171	Hydroxychloroquine inhibits IL-1 $\beta$ production from amyloid-stimulated human neutrophils. <b>2019</b> , 21, 250	13
170	Pharmacologic Management of Rheumatoid Arthritis. <b>2019</b> , 38, 390-395	
169	Antimalarial Medications. <b>2019</b> , 650-660	
168	Lupresan, a new drug that prevents or reverts the formation of nonbilayer phospholipid arrangements that trigger a murine lupus resembling human lupus. <b>2019</b> , 509, 275-280	2
167	A Case-Based Guide to Neuromuscular Pathology. <b>2020</b> ,	0
166	Treatment of Autoimmune Disease: Established Therapies. <b>2020</b> , 1415-1435	

165	Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. <b>2020</b> , 12, 91-94	14
164	Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage. <b>2020</b> , 86, 39-49	9
163	Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. <b>2020</b> , 29, 79-82	2
162	Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. <b>2020</b> , 2020, 4582612	9
161	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. <b>2020</b> , 6, e04900	9
160	Degradation of hydroxychloroquine by electrochemical advanced oxidation processes. <b>2020</b> , 402, 126279	34
159	Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. <b>2021</b> , 39, 5792-5798	15
158	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. <b>2020</b> , 21,	11
157	Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19. <b>2020</b> , 1-16	3
156	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. <b>2020</b> , 46, 574-578	8
155	Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19. <b>2020</b> , 24, 568-580	27
154	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?. <b>2020</b> , 28, 266-271	8
153	Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. <b>2020</b> , 22, 15	12
152	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. <b>2020</b> , 25, 497-502	2
151	Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. <b>2020</b> , 11, 1409	27
150	DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA. <b>2020</b> , 228-236	1
149	Emerging therapeutics for the management of COVID 19. <b>2020</b> , 25, 337-351	5
148	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. <b>2020</b> , 13, 531-542	5

147	Autophagy in tumor and tumor microenvironment. <b>2020,</b>	
146	COVID-19 update: The race to therapeutic development. <b>2020, 53, 100733</b>	33
145	Targeting Crucial Host Factors of SARS-CoV-2. <b>2020, 6, 2844-2865</b>	13
144	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <b>2020, 11, 582025</b>	11
143	Pregnancy in systemic lupus erythematosus. <b>2020, 112, 1115-1125</b>	2
142	Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. <b>2020, 42, 25</b>	8
141	Rapid response to combination of hydroxychloroquine and prednisolone in a patient with refractory hypocomplementemic urticarial vasculitis. <i>Dermatologic Therapy</i> , <b>2020, 33, e14531</b>	2.2
140	Reviewing the Effects of Miltefosine and Suggesting It for the Treatment of Coronavirus Disease (COVID-19). <b>2020, 13, 1178633720977488</b>	
139	Protein-ligand binding interactions of imidazolium salts with SARS CoV-2. <b>2020, 6, e05544</b>	3
138	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. <b>2020, 27, 493-504</b>	78
137	The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?. <i>Dermatologic Therapy</i> , <b>2020, 33, e13607</b>	2.2
136	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. <b>2020, 382, 2411-2418</b>	1063
135	Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. <b>2020, 213, 107587</b>	131
134	Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. <b>2020, 7,</b>	30
133	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. <b>2020, 16, 2260-2266</b>	40
132	COVID-19 and hydroxychloroquine: Is the wonder drug failing?. <b>2020, 78, 1-3</b>	7
131	In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <b>2020, 71, 732-739</b>	1644
130	Long Term Pharmacological Perturbation of Autophagy in Mice: Are HCQ Injections a Relevant Choice?. <b>2020, 8,</b>	2

129	Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. <b>2020</b> , 143, 110051	14
128	A Zebra at the Rodeo: Dyspnea, Hematuria, and a Family History of Arthritis. <b>2020</b> ,	0
127	Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy. <b>2020</b> , 21, e243-e245	
126	A joint effort: The interplay between the innate and the adaptive immune system in Lyme arthritis. <b>2020</b> , 294, 63-79	5
125	Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. <b>2020</b> , 9,	100
124	Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. <b>2020</b> , 13, 642-645	28
123	SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis. <b>2020</b> , 20, e00778	7
122	Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. <b>2020</b> , 35, 100684	48
121	Hydroxychloroquine treatment for Alopecia Universalis: Report of six cases. <b>2021</b> , 62, e83-e85	1
120	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. <b>2021</b> , 75, e13825	5
119	Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2. <b>2021</b> , 287, 113995	18
118	Repurposing medications. <b>2021</b> , 19, 336-340	4
117	Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. <b>2021</b> , 376, 261-272	2
116	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. <b>2021</b> , 11, 731-753	28
115	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134	26
114	Introduction on Treatment for Infectious Diseases and Immunological Disorders. <b>2021</b> ,	
113	study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase. <b>2021</b> , 1-18	7
112	Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. <b>2020</b> , 11, 602880	0

111	Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. <b>2021</b> , 22, 62-66	2
110	Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients. <b>2020</b> , 11, 585021	2
109	Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2. <b>2021</b> , 1-16	10
108	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <b>2021</b> , 27, 115-126	7
107	Reasoned therapeutic protocol in outpatients with COVID-19. <b>2021</b> , 40, 170-175	0
106	COVID-19, hydroxychloroquine and the importance of disease progression. <b>2021</b> , 10, 299-311	1
105	Cyclodextrin-mediated gold nanoparticles as multisensing probe for the selective detection of hydroxychloroquine drug. <b>2021</b> , 38, 624-634	4
104	4-Aminoquinoline compounds from the Spanish flu to COVID-19. <b>2021</b> , 135, 111138	3
103	Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19. <b>2021</b> , 8, 642313	3
102	Therapeutic Agents for COVID-19: an Overview. <b>2021</b> , 16, 22-44	1
101	New Trends On Biological Activities And Clinical Studies Of Quinolinic Analogues: A Review. <b>2021</b> ,	
100	Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis. <b>2021</b> , 31, 1135-1141	2
99	Effect of Hydroxychloroquine on Lipid Levels: A Systematic Review and Metaanalysis. <b>2021</b> , 27, 4133-4139	2
98	Hydroxychloroquine Induced DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) Mimicking SARS-COV-2 Illness: A Case Report with Review. <b>2021</b> , 2, 521-526	
97	Acute Pyogenic Osteomyelitis of the Pubic Bone in a Patient with Systemic Lupus Erythematosus Mimicking Fracture of the Pubic Bone and Periprosthetic Joint Infection of the Hip. <b>2021</b> , 2021, 6665938	1
96	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. <b>2021</b> , 17,	0
95	Hydroxychloroquine-associated pigmentation after extravasation injury. <b>2021</b> , 12, 46-48	
94	Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 4665-4670	3.9 4

93	Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. <b>2021</b> , 174, 106675	5
92	Novel Therapeutic Interventions in Systemic Lupus Erythematosus.	
91	Inhibition of autophagy mitigates cell migration and invasion in thyroid cancer. <b>2021</b> ,	1
90	Nanoparticles as an effective drug delivery system in COVID-19. <b>2021</b> , 143, 112162	4
89	Cytokine Storm and Immunomodulation in COVID-19: a Review. <b>2021</b> , 02,	
88	On the importance of physicochemical parameters of copper and aminosilane functionalized mesoporous silica for hydroxychloroquine release. <b>2021</b> , 130, 112438	2
87	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. <b>2021</b> , 21, 5	4
86	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. <b>2021</b> , 73, 750-768	6
85	Hydroxychloroquine. <b>2005</b> , 81-92	5
84	Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. <b>2020</b> , 28, 1333-1352	11
83	ANTIMALARIAL AGENTS AND LUPUS. <b>1994</b> , 20, 243-263	96
82	Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?. <b>1997</b> , 64, 1055-65	15
81	Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2. <b>2020</b> ,	16
80	Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.	2
79	Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. <b>2016</b> , 126, 4417-4429	52
78	Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. <i>PLoS ONE</i> , <b>2013</b> , 8, e65913	3-7 52
77	Effect of hydroxychloroquine on oxidative/nitrosative status and angiogenesis in endothelial cells under high glucose condition. <b>2017</b> , 7, 219-226	11
76	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <b>2020</b> , 12, e12476	29



75	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. <b>2020</b> , 26, 4467-4485	17
74	Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. <b>2020</b> , 21, 1127-1135	7
73	Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). <b>2020</b> , 18, 455-462	0
72	Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations. <b>2020</b> , 2, 68-74	1
71	Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression. <b>2016</b> , 47, 207-17	3
70	The VR23 Antitumor Compound Also Shows Strong Anti-Inflammatory Effects in a Human Rheumatoid Arthritis Cell Model and Acute Lung Inflammation in Mice. <b>2020</b> , 204, 788-795	4
69	Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments. <b>2019</b> , 10, 477-522	3
68	Wide Applications of Chloroquine Other Than Antimalarial. <b>2020</b> , 11, 251-281	1
67	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. <b>2019</b> , 8,	25
66	Chloroquine and hydroxychloroquine in the context of COVID-19. <b>2020</b> , 9,	23
65	One step derivatization and dispersive liquid-liquid microextraction of hydroxychloroquine sulfate for its sensitive and accurate determination using GC-MS. <b>2021</b> , 107130	1
64	Current trends in diagnosis and treatment strategies of COVID-19 infection. <b>2021</b> , 28, 64987-65013	2
63	Immune System Modulators. <b>2001</b> ,	
62	ANTIMALARIALS AND IMMUNOSUPPRESSIVE THERAPIES. <b>2004</b> , 1273-1293	
61	Tissue distribution and tumor concentrations of hydroxychloroquine and quinacrine analogs in mice.	1
60	Characteristics of Visual Electrophysiology in Retinal Toxicities. <b>2019</b> , 173-190	
59	A Swollen Leg. <b>2019</b> , 27, 55-57	1
58	A 42-Year-Old Woman with Progressive Limb Weakness and Breathing Difficulty. <b>2020</b> , 221-227	

57	Mechanisms of Autoimmunity and Pharmacologic Treatments. <b>2020</b> , 207-249		
56	Management of Chronic Urticaria. <b>2020</b> , 85-92		
55	Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic. <b>2020</b> , 6, 006-008		
54	COVID-19: The possible medical strategies. <b>2020</b> , 4, 071-075		
53	COVID-19: A Centennial Pandemic from Origin to Clinical Trials. <b>2020</b> , 3, 30-52		1
52	Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options. <b>2021</b> , 32, 57-65		0
51	Targeting Autophagy in Cancer: Therapeutic Implications. <b>2020</b> , 249-264		
50	Potential Drugs for Treating COVID-19 Infection. <b>2020</b> , 7,		
49	The Benefits of Antiviral Use of Chloroquine Versus its Potential Cardiovascular Side Effects. <b>2020</b> , 61, 863-864		
48	Hydroxychloroquine and the risk of respiratory infections among RA patients. <b>2020</b> , 6,		1
47	Chloroquine has not disappeared. <b>2007</b> , 7, 185-6		5
46	Hydroxychloroquine in Dermatology and Beyond: Recent Update. <i>Indian Dermatology Online Journal</i> , <b>2020</b> , 11, 453-464	0.9	5
45	Toxicidade ocular por cloroquina. <b>2014</b> , 39-42		
44	Hydroxychloroquine in dermatology and beyond: Recent update. <i>Indian Dermatology Online Journal</i> , <b>2020</b> , 11, 453	0.9	10
43	Immunosuppression in Rheumatologic and Auto-immune Disease. <i>Handbook of Experimental Pharmacology</i> , <b>2021</b> , 1	3.2	1
42	Intracellular TLRs of Mast Cells in Innate and Acquired Immunity. <i>Handbook of Experimental Pharmacology</i> , <b>2021</b> ,	3.2	1
41	The pharmacotherapeutics of sarcoidosis.. <i>Expert Review of Clinical Pharmacology</i> , <b>2022</b> , 1-14	3.8	
40	The Potential Benefit of Hydroxychloroquine in Chronic Placental Inflammation of Unknown Etiology Associated with Adverse Pregnancy Outcomes.. <i>Healthcare (Switzerland)</i> , <b>2022</b> , 10,	3.4	0

39	Vascular endotheliitis associated with infections: its pathogenetic role and therapeutic implication.. <i>Biochemical Pharmacology</i> , <b>2022</b> , 197, 114909	6	1
38	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , <b>2021</b> , 7, 28-70	0.1	
37	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X211073001	3.8	5
36	Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma. <i>Journal of Primary Care Specialties</i> , <b>2022</b> , 3, 3	0	
35	A case of Melkersson-Rosenthal syndrome successfully treated with hydroxychloroquine.. <i>Dermatologic Therapy</i> , <b>2022</b> , e15409	2.2	
34	Different Drugs, Same End: Ultrastructural Hallmarks of Autophagy in Pathogenic Protozoa.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 856686	5.7	1
33	Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0266337	3.7	2
32	Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.. <i>Journal of International Medical Research</i> , <b>2022</b> , 50, 3000605221090363	1.4	
31	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. <i>International Journal of Infectious Diseases</i> , <b>2022</b> ,	10.5	0
30	Amphiphilic Myopathy Induced by Hydroxychloroquine Presenting with Dysarthria. <i>Daehan Sin-gyeong Geunyuk Jilhwan Hakoeji</i> , <b>2021</b> , 13, 52-54	0	
29	Data_Sheet_1.docx. <b>2020</b> ,		
28	Table_1.xlsx. <b>2020</b> ,		
27	Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia. <i>Toxicology and Applied Pharmacology</i> , <b>2022</b> , 116084 <sup>4.6</sup>		
26	Multi-Targeted Molecular Docking and Drug-Likeness Evaluation of some Nitrogen Heterocyclic Compounds Targeting Proteins Involved in Development of COVID-19. <i>Medicinal Chemistry</i> , <b>2022</b> , 18,	1.8	
25	Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). <i>Journal of Heterocyclic Chemistry</i> ,	1.9	0
24	Impact of gamma-irradiation on the degradation and mineralization of hydroxychloroquine aqueous solutions. <i>International Journal of Environmental Science and Technology</i> ,	3.3	1
23	Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. <i>Clinical Rheumatology</i> ,	3.9	
22	Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. <b>2022</b> , 97, 1551-1571		

21	A multidimensional metabolomics workflow to image biodistribution and evaluate pharmacodynamics in adult zebrafish. <b>2022</b> , 15,	0
20	A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated <i>Caenorhabditis elegans</i> screening platform. <b>2022</b> , 8, e10108	
19	Drugs to limit Zika virus infection and implication for maternal-fetal health. 2,	
18	Neuroinflammation in Multiple Sclerosis. <b>2022</b> ,	0
17	NLRP3 inflammasome activation and its inhibitory drugs in connection with COVID-19 infection. <b>2022</b> , 20, 1721727X2211309	0
16	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.	0
15	Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: a real-world study.. <b>2022</b> ,	0
14	Consensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification. <b>2022</b> , 130,	2
13	Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring. <b>2022</b> ,	0
12	Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus. <b>2023</b> ,	0
11	Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment.	0
10	Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by Quinacrine, Chloroquine, and Structurally Related Compounds. <b>1998</b> , 160, 1122-1131	43
9	Biotransformation of hydroxychloroquine to evaluate the cytotoxicity of its metabolites and mimic mammalian metabolism. <b>2023</b> , 5, 100761	0
8	Hydroxychloroquine: Chemistry and Medicinal Applications. <b>2023</b> , 106,	0
7	Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: A randomized, multicenter, placebo-controlled trial (HERO-HCQ). <b>2023</b> ,	1
6	An efficient weighted network centrality approach for exploring mechanisms of action of the <i>Ruellia</i> herbal formula for treating rheumatoid arthritis. <b>2023</b> , 8,	0
5	Time-lapse proteomics unveil constant high exposure of non-antibiotic drug induces synthetic susceptibility towards regular antibiotics. <b>2023</b> , 269, 127320	0
4	Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis. 1-7	0

- 3 The HIT Study: The Hydroxychloroquine Effect in the Treatment of Patients with Age-Related Macular Degeneration: A Randomized Controlled Trial. **2023**, 59, 551
- 2 Predicting Hydroxychloroquine Clearance in healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach. **2023**, 15, 1250
- 1 Knockout of the neonatal Fc receptor alters immune complex trafficking and lysosomal function in cultured podocytes. **2023**, 18, e0284636